Dr. Len's Cancer Blog

Expert perspective, insight and discussion

Dr. Len's Cancer Blog

The American Cancer Society

During Breast Cancer Awareness Month We Must Not Only Celebrate Our Success But Also Understand Our Limitations

by Dr. Len October 03, 2012

I find myself sitting here to write a blog in recognition of Breast Cancer Awareness month, and frankly it's not as easy as I anticipated. And I am asking myself why that is.

 

We have made considerable progress in the early detection of breast cancer. I have commented frequently about the differences in breast cancer detection, treatment and survival today and when I started my medical training and career in the 1970's.

 

Early detection is clearly a success story if the measure of success is whether or not we can find breast cancer when it is "small" in most women. Our technology lets us do that with mammography techniques that are far more accurate and sophisticated than they were a few decades ago. Much of our discussion today centers around what role newer approaches, such as MRI, ultrasound, and most recently 3-D mammography have in early detection of breast cancer.

 

Our treatments are much more refined than they were in 1970, as well. We now have lumpectomy and radiation as a valid replacement for many mastectomies. We have sentinel node biopsy instead of axillary node dissection, which for some women adds nothing but long term misery caused by swelling of the arm. We have hormone-related treatments, chemotherapies, and biologic therapies that can prevent cancer from recurring; and we have an increasing number of promising approaches to treat the disease if it does come back.

 

We have genetic tests that can help pinpoint women at higher risk of developing breast cancer, and others that can help some women and their doctors decide whether or not they need to receive chemotherapy as part of their adjuvant (preventive) treatment after primary treatment with surgery.

 

We certainly have increased awareness of breast cancer beyond anything imagined in 1970. It's hard to imagine, but back then, cancer was not discussed in polite company (really). Some women did everything they could to hide their disfigurement and even what they thought was their "shame." Today, breast cancer is discussed openly and frankly (most of the time), and the voice of advocates is being heard at levels never dreamed of decades ago.

 

So with all this progress, why shouldn't I be celebrating our successes?

 

I don't want to be too pessimistic, so I will agree that we do have reason to be proud of our progress. We are saving lives; we have reduced disfiguring treatments; we can make a difference as individuals and communities concerned about this disease.

 

But I fear that at times we have oversold our magic. I fear that despite all the progress and all the understanding about the disease, we still have too many women who either can't get access to quality mammography, who can't afford treatment, or who go bankrupt in the process. I fear that we have set expectations too high, while we are learning that our science is not as perfect as we would like it to be. I fear that we have too many tests chasing too few women for whose benefit some of the prescribed "solutions" are far from proven. I fear we have overpromised and sometimes underdelivered.

 

But this is a month of celebration, isn't it?

 

Perhaps celebration isn't the right word. Perhaps this is a month to celebrate awareness, to celebrate our successes, but also to acknowledge our limitations and recommit ourselves to improving our science and better applying our knowledge. Perhaps we should take an opportunity during this month to reflect on what we know, what we don't know, what we would like to know, and how we can marshal our collective will to do better.

 

Just so the record is clear: I do think mammograms save lives. Perhaps their role has been less dominant with the emergence of effective surgical approaches and treatments to reduce the risk of cancer's return. But they do still have a role. I do believe we are on the cusp of significant advances in the understanding of the basic biology of breast cancer, as reflected in comments I made recently about a new study reporting on the most comprehensive analysis of breast cancer genes done to date.

 

At the same time, I understand the anger of women with advanced breast cancer who say, "What about me?" Among these women are those who did everything "right" when it came to early detection and treatment. And among these are women who couldn't do everything "right" because they couldn't access the system or couldn't find someone to treat them in a proper and timely fashion. These are women who pray for a breakthrough, who pray for a cure and wonder whether those who have not been diagnosed with breast cancer or who don't have advanced disease really understand.

 

So here is the way I look at my dilemma: I praise the successes, but I also accept the limitations. And I pray for the day when our science takes us to the place where breast cancer is indeed a remnant of the past-for all women. I search for science that will help guide us through some of the confusing messaging surrounding early detection, and ways to be certain all women have access to care.

 

So maybe I am out of the mainstream of the "celebration." I know our limitations. We aren't there yet, and frankly we have a long way to go. But I remain eternally optimistic that we are going to get to a better place, when celebration is justified. But for me, it's just a bit early right now. There is still much to learn, and much to do.

Comments

10/4/2012 9:47:20 AM #

Gregory Pawelski

As you pointed out Dr. Len, the implications of the research "also points out the incredible complexity of the disease." The research is incredibly complex. One of the questions raised about separating the real signals from the background "chatter" is that patients will think because they are being completely genotyped, this will give all the answers needed for information in significant drug selection value.

What is more important than what genes are in the DNA, is what genes are actively making RNA, which RNA is actively making protein, which protein is being turned off or turned on, and how all of the proteins in the cell are interacting with each other. The only way to get the latter information, which is ultimately what you want, is to treat the patient with phenotype analysis.

Yes, the research is exciting, but as you have said, the path remains long and arduous. The American Association of Cancer Research (AACR) is the premier cancer research organization for basic and translational research. Their focus is often geared toward PhD level scientific discovery. Their meetings provide the most informative insights into therapy options that may not arrive in the clinical arena for many years.

At a recent AACR meeting, one laboratory oncologist commented that he was not sure he heard the word "chemotherapy" a single time. That is, all of the alphabet soup combinations that make up sessions at other venues, are nowhere to be found at the AACR meeting. Instead, targeted agents, genomics, proteomics and the growing field of metabolomics reign supreme.

Much like genomics aims to unravel the structure of the genome, metabolomics focuses on understanding the many small molecule metabolites that result from a cell's metabolic processes. For research, the study of metabolomics provides the means to measure the effects of a variety of stimuli on individual cells, tissues, and bodily fluids.

By studying how their metabolic profiles change with the introduction of chemicals or the expression of known genes, researchers can more effectively study the immediate impact of disease, nutrition, pharmaceutical treatment, and genetic modifications while using a systems biology approach.

Gregory Pawelski

10/4/2012 6:00:29 PM #

Elaine Schattner, MD

Hi Len,
I agree that breast cancer is nothing to celebrate. But I'm genuinely optimistic about BC treatments and prognosis improving, because there's been so much progress in the relevant science and pathology - understanding disease subtypes - over the past 15 years. The problem, in my view, is largely that the work (and mindset) of doctors in the clinic lags behind the science.

Elaine Schattner, MD

10/8/2012 6:55:14 PM #

BlondeAmbition

I'm very pleased to see this viewpoint. The breast cancer 'conversation' has indeed changed from the 1970s but it's also morphed into a perverted kind of awareness that has commercialized and branded a serious disease beyond recognition. The discussion needs to change again and reel the merrymakers back to reality. I don't disagree that we must embrace and celebrate the successes --- but as you point out, the promises have been oversold. People don't like to think of recurrence and remain blissfully unaware that this can even happen from a Stage 0 or Stage 1 diagnosis because metastasis is not fully understood. I hope that you and your colleagues continue to right the ship.

BlondeAmbition

10/9/2012 12:03:08 PM #

The Rev. Pamela J. Breakey

Dr. Len,

If you read this, could you please do something about the horrible fundraiser that the ACS in "Michiana", the rural area of SW Michigan and Northern Indiana around South Bend, is doing with pink garbage trollies!  It is very upsetting to be out driving and see pepto pink garbage trollies representing breast cancer!  Are we garbage for having bc?  While I laud all those who contribute their $10 a month to the ACS, there has got to be a better way than pink garbage trollies!  

Thank you.  

The Rev. Pamela J. Breakey

Add comment


(Will show your Gravatar icon)

biuquote
  • Comment
  • Preview
Loading



About Dr. Len

Dr. Len

J. Leonard Lichtenfeld, MD, MACP - Dr. Lichtenfeld is Deputy Chief Medical Officer for the national office of the American Cancer Society.

MORE »

 

Recent Comments

Comment RSS